INKT · TickerCove

INKTMiNK Therapeutics, Inc.Healthcare · Biotechnologyas of 2026-09-16

Horizon

Issued 2026-09-16 at $11.59 · now $11.59 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, INKT has typically landed between $7.64 and $17.84 — a range of −34.1% to +53.9% from the issuance price $11.59.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.

Actual close
Typical path (median)
Middle 50% of outcomes
90% range

1,211 overlapping 1 month windows · 2021-10-15 – 2026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.7–56.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($11.59) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

52-week range$11.59 · 39% of range

$8.56 low$16.3 high

Trailing 52 weeks to 2026-09-16 — factual context, not a signal.

Base rate up · monthiClimatology base rate that a US-listed stock rises over a month, with its 90% CI and ≈1,408 effective observations. Not a call on this stock — we have no evidence its odds differ.

53.9%

90% CI 51.7%–56.1%

Distribution · month iiThe price-anchored range: typical move (median), and the p90 downside/upside — 90% of similar periods stayed inside these. Ranges, not a prediction of direction.

−4.5%

typical move · IQR 19.3%

−34.1%worst (p90)+53.9%best (p90)

Insider convictioniOpen-market common-stock purchases by company insiders in the last 90 days (grants and option exercises excluded). Historical tendency, not advice — detail below.

conviction buys

0 open-market sales

Congress disclosuresiRecent disclosed congressional trades for this company. Purchase clusters (≥2 members buying within 90 days) historically preceded a modestly higher forward return (+32 bp/mo in 2022–2026, +45 bp/mo in 2015–2021) — a descriptive tendency, not a forecast input. Detail below.

0 buys · 0 sells · 0 members

cluster tilt persisted, ~halved after 2021

Where INKT has typically landed a month from the 2026-09-16 close of $11.59 — the range is history, not a prediction.

now $11.59 (+0.0%)
typical $11.06 (-4.5%)
middle 50% $9.95–$12.18
90% range $7.64–$17.84

Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 1,211 windows spanning 2021-10-15 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.

Start	Return	Max drop	Max rise
3 worst
2021-11-26	−79.0%	−79.4%	+0.0%
2021-11-24	−77.1%	−78.0%	+6.7%
2021-11-22	−75.6%	−75.6%	+18.6%
3 best
2025-06-10	+435.8%	−7.9%	+435.8%
2025-06-11	+269.0%	−8.0%	+435.0%
2025-06-13	+220.7%	−3.7%	+460.1%

1,211 overlapping windows · 2021-10-15 – 2026-09-16 · not cherry-picked

Seasonality · by month i

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~5 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.

Jan

40%

−4.1%

n=5

Feb

20%

−4.8%

n=5

Mar

−7.9%

n=5

Apr

40%

+1.0%

n=5

May

−8.0%

n=5

Jun

40%

+1.8%

n=5

Jul

20%

+15.2%

n=5

Aug

40%

+12.8%

n=5

Sep

20%

−9.7%

n=5

Oct

50%

−2.1%

n=4

Nov

60%

−6.6%

n=5

Dec

40%

−12.0%

n=5

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Date	Person	Role	Action	Shares @ price	Value	Ownership Δ	vs S&P 1m	vs S&P 6m	Owned after	Filing
2026-06-04	Ryan Barbara	director	Sale	1,000 @ $12.80	$13K	−4.4% of holding	−15.7%	not yet — horizon still open	21,969	Form 4 · filed 1 day after the trade
2026-06-04	Ryan Barbara	director	Sale	500 @ $12.68	$6K	−2.1% of holding	−15.7%	not yet — horizon still open	22,969	Form 4 · filed 1 day after the trade
2026-03-10	Ryan Barbara	director	Sale	500 @ $15.57	$8K	−2.3% of holding	−15.8%	−25.1%	20,906	Form 4 · filed 1 day after the trade
2026-03-10	Ryan Barbara	director	Sale	500 @ $15.30	$8K	−2.4% of holding	−15.8%	−25.1%	20,406	Form 4 · filed 1 day after the trade
2026-03-10	Ryan Barbara	director	Sale	300 @ $15.28	$5K	−1.4% of holding	−15.8%	−25.1%	21,406	Form 4 · filed 1 day after the trade
2026-03-09	Ryan Barbara	director	Sale	200 @ $10.17	$2K	−0.9% of holding	+6.8%	−4.0%	21,706	Form 4 · filed 2 days after the trade
2026-03-02	Ryan Barbara	director	Sale	100 @ $10.83	$1K	−0.5% of holding	+1.6%	−10.6%	21,906	Form 4 · filed 2 days after the trade
2026-02-27	Ryan Barbara	director	Sale	400 @ $10.86	$4K	−1.8% of holding	+3.7%	−8.4%	22,006	Form 4 · filed 5 days after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

52 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

Date	Person	Role	Action	Shares	Owned after	Filing
2026-09-01	Corvese Brian	director	Award / grant	1,633	54,770	Form 4
2026-09-01	Ryan Barbara	director	Award / grant	1,622	23,591	Form 4
2026-09-01	Behner Peter	director	Award / grant	1,485	24,404	Form 4
2026-09-01	WIINBERG ULF	director	Award / grant	1,279	23,929	Form 4
2026-09-01	Holcomb John Bradley	director	Award / grant	1,233	4,691	Form 4
2026-06-01	Corvese Brian	director	Award / grant	1,444	53,137	Form 4
2026-06-01	Ryan Barbara	director	Award / grant	1,434	23,469	Form 4
2026-06-01	Behner Peter	director	Award / grant	1,313	22,919	Form 4
2026-06-01	WIINBERG ULF	director	Award / grant	1,131	22,650	Form 4
2026-06-01	Holcomb John Bradley	director	Award / grant	1,091	3,458	Form 4
2026-03-02	Corvese Brian	director	Award / grant	1,640	51,693	Form 4
2026-03-02	Ryan Barbara	director	Award / grant	1,629	22,035	Form 4
2026-03-02	Behner Peter	director	Award / grant	1,491	21,606	Form 4
2026-03-02	WIINBERG ULF	director	Award / grant	1,285	21,519	Form 4
2026-03-02	Holcomb John Bradley	director	Award / grant	1,239	2,367	Form 4
2026-01-02	Buell Jennifer	director	Award / grant	31,474	67,966	Form 4
2026-01-02	Ryan Barbara	director	Award / grant	5,395	5,395	Form 4
2026-01-02	Buell Jennifer	director	Award / grant	50,000	50,000	Form 4
2026-01-02	Behner Peter	director	Award / grant	5,395	5,395	Form 4
2026-01-02	Corvese Brian	director	Award / grant	5,395	5,395	Form 4
2026-01-02	WIINBERG ULF	director	Award / grant	5,395	5,395	Form 4
2025-12-01	Corvese Brian	director	Award / grant	1,612	50,053	Form 4
2025-12-01	Ryan Barbara	director	Award / grant	1,601	22,406	Form 4
2025-12-01	Behner Peter	director	Award / grant	1,466	20,115	Form 4
2025-12-01	WIINBERG ULF	director	Award / grant	1,263	20,234	Form 4
2025-12-01	Kadlec Robert Peter	director	Award / grant	1,218	19,126	Form 4
2025-12-01	Holcomb John Bradley	director	Award / grant	1,128	1,128	Form 4
2025-09-23	Holcomb John Bradley	director	Award / grant	4,174	4,174	Form 4
2025-09-09	Buell Jennifer	director	Award / grant	18,229	41,913	Form 4
2025-09-09	Corvese Brian	director	Award / grant	3,225	3,225	Form 4
2025-09-09	Behner Peter	director	Award / grant	3,225	3,225	Form 4
2025-09-09	Ryan Barbara	director	Award / grant	3,225	3,225	Form 4
2025-09-09	WIINBERG ULF	director	Award / grant	3,225	3,225	Form 4
2025-09-09	Buell Jennifer	director	Award / grant	50,000	50,000	Form 4
2025-09-09	Kadlec Robert Peter	director	Award / grant	3,225	3,225	Form 4
2025-09-02	Corvese Brian	director	Award / grant	1,290	48,441	Form 4
2025-09-02	Ryan Barbara	director	Award / grant	1,281	20,805	Form 4
2025-09-02	Behner Peter	director	Award / grant	1,173	18,649	Form 4
2025-09-02	WIINBERG ULF	director	Award / grant	1,011	18,971	Form 4
2025-09-02	Kadlec Robert Peter	director	Award / grant	975	17,908	Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Resolves in i

28d remaining

2026-09-173% elapsed2026-10-15

Logged immutably 2026-09-17; scored automatically on 2026-10-15 — no edits, ever.

Earnings & context analysis

These panels are being prepared. They are generated by multiple language models, checked, and stored before display — never written live for a page view. Until a model panel has been generated and reviewed for a company, nothing is shown here, honestly, rather than a placeholder.

Calibration i

Every forecast is logged when made and scored when the month is up. The record is shown from the day it starts — young and honest.

How scoring works →

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

Reported insider & political trades

Congressional disclosures

Seasonality · by month i